Downregulation of GLYAT correlates with tumour progression and poor prognosis in hepatocellular carcinoma
Journal of Cellular and Molecular Medicine · 2024
DOI: 10.1111/jcmm.70197 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cellular and Molecular Medicine, 2024. Verfasst von Fengchen Jiang und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Interventional Angiology, Affiliated Nantong Hospital 3 of Nantong University, Nantong, China. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Disease Progression, Gene Expression Regulation, Neoplastic. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Nantong Science and Technology Project, Science and Technology Project of Nantong City.
Abstract (Originalsprache)
Glycine N‐acyltransferase (GLYAT), known to influence glycine metabolism, has been implicated in the progression of various malignant tumours. However, its clinical relevance in hepatocellular carcinoma (HCC) remains unexplored. Here, GLYAT expression levels in HCC tissues were significantly reduced compared to normal liver tissues. Similarly, GLYAT expression levels in Huh 7, HepG2, PLC and SK‐HEP1 were lower than those in LO2. Receiver operating characteristic curve analysis demonstrated that GLYAT exhibited good diagnostic performance for HCC. Kaplan–Meier analyses suggested that decreased GLYAT expression was correlated with poorer progress in HCC. Low GLYAT expression was significantly associated with gender and histologic grade. Multivariate Cox regression analysis identified low GLYAT expression and T stage as independent prognostic factors. Nomograms based on GLYAT mRNA expression and T stage showed good concordance with actual survival rates at 1, 2, 3 and 5 years. Moreover, GLYAT downregulation in the Huh 7 cell line enhanced cell proliferation, invasion and migration abilities, while GLYAT overexpression in the HepG2 cell line inhibited these abilities. HCC patients with low GLYAT expression exhibited a predisposition to immune escape and poor response to immunotherapy. This research revealed that GLYAT holds promise as both a prognostic biomarker and a potential therapeutic target in HCC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Interventional Angiology, Affiliated Nantong Hospital 3 of Nantong University, Nantong, China.
- Comparative Medicine Institution, Nantong University, Nantong, China.
- School of Medicine, Nantong University, Nantong, China.
ORCID-Profile: Fengchen Jiang
Förderung
- Nantong Science and Technology Project
- Science and Technology Project of Nantong City
Zitieren
APA
Jiang, F., Zhou, S., Xia, C., Lu, J., Wang, B., Wang, X., Shen, J., Ding, W., Yin, M., Dai, F., & Fu, S. (2024). Downregulation of GLYAT correlates with tumour progression and poor prognosis in hepatocellular carcinoma. Journal of Cellular and Molecular Medicine. https://doi.org/10.1111/jcmm.70197
Vancouver
Jiang F, Zhou S, Xia C, Lu J, Wang B, Wang X, et al. Downregulation of GLYAT correlates with tumour progression and poor prognosis in hepatocellular carcinoma. Journal of Cellular and Molecular Medicine. 2024. doi:10.1111/jcmm.70197
BibTeX
@article{Jiang2024,
author = {Jiang, Fengchen and Zhou, Shuiping and Xia, Chuanlong and Lu, Jiale and Wang, Bin and Wang, Xiaowei and Shen, Jiandong and Ding, Wei and Yin, Mengjie and Dai, Feng and Fu, Shouzhong},
title = {Downregulation of GLYAT correlates with tumour progression and poor prognosis in hepatocellular carcinoma},
journal = {Journal of Cellular and Molecular Medicine},
year = {2024},
doi = {10.1111/jcmm.70197}
}
EUVIMED